HK1134508A1 - Antibodies against c5 inhibiting type ii endothelial cell activation ii c5 - Google Patents
Antibodies against c5 inhibiting type ii endothelial cell activation ii c5Info
- Publication number
- HK1134508A1 HK1134508A1 HK10102519.6A HK10102519A HK1134508A1 HK 1134508 A1 HK1134508 A1 HK 1134508A1 HK 10102519 A HK10102519 A HK 10102519A HK 1134508 A1 HK1134508 A1 HK 1134508A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- endothelial cell
- cell activation
- inhibitors
- antibodies against
- inhibiting type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23930900P | 2000-10-10 | 2000-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1134508A1 true HK1134508A1 (en) | 2010-04-30 |
Family
ID=22901599
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102519.6A HK1134508A1 (en) | 2000-10-10 | 2010-03-10 | Antibodies against c5 inhibiting type ii endothelial cell activation ii c5 |
HK15111863.4A HK1211043A1 (en) | 2000-10-10 | 2015-12-02 | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 |
HK16113934A HK1225741A1 (zh) | 2000-10-10 | 2016-12-07 | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111863.4A HK1211043A1 (en) | 2000-10-10 | 2015-12-02 | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection c5 |
HK16113934A HK1225741A1 (zh) | 2000-10-10 | 2016-12-07 | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6534058B2 (fr) |
EP (5) | EP1325033B1 (fr) |
AT (1) | ATE449791T1 (fr) |
AU (1) | AU2001296594A1 (fr) |
CA (1) | CA2424379C (fr) |
DE (1) | DE60140618D1 (fr) |
DK (1) | DK1325033T3 (fr) |
ES (2) | ES2483991T3 (fr) |
HK (3) | HK1134508A1 (fr) |
PT (1) | PT1325033E (fr) |
WO (1) | WO2002030985A2 (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7361742B2 (en) * | 2002-12-02 | 2008-04-22 | Resistentia Pharmaceuticals Ab | Methods and materials for treating inflammatory conditions |
US20070123466A1 (en) * | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
CA2560066A1 (fr) | 2004-03-01 | 2005-09-15 | The Cbr Institute For Biomedical Research, Inc. | Anticorps naturels igm et leurs inhibiteurs |
US20090028850A1 (en) | 2004-05-14 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
NZ567483A (en) | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
AU2013200223B2 (en) * | 2005-11-04 | 2015-08-20 | Genentech, Inc. | Use of Complement Pathway Inhibitors to Treat Ocular Diseases |
CN101437501B (zh) * | 2006-03-02 | 2012-09-05 | 阿莱克申药物公司 | 通过抑制补体活性延长同种异体移植物的存活 |
SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
AU2007293013B2 (en) | 2006-09-05 | 2013-06-27 | Alexion Pharmaceuticals, Inc. | Method and compositions for the treatment of antibody mediated neuropathies |
EP2907827B1 (fr) * | 2006-11-02 | 2018-09-19 | Genentech, Inc. | Anticorps humanisés anti-facteur D et leurs utilisations |
WO2008097525A2 (fr) | 2007-02-05 | 2008-08-14 | Potentia Pharmaceuticals, Inc. | Inhibition locale de complément destinée au traitement de troubles induits par le complément |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
AU2014201433B2 (en) * | 2008-08-05 | 2016-05-26 | Novartis Ag | Compositions and methods for antibodies targeting complement protein C5 |
JP5815403B2 (ja) * | 2008-08-05 | 2015-11-17 | ノバルティス アーゲー | 補体タンパク質c5を標的とする抗体に関する組成物および方法 |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
CA2774260C (fr) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Anticorps anti-cea de classe i et leurs utilisations |
EP2506881B1 (fr) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combinaison de radioimmunotherapie et conjugues anticorps-medicament pour une meilleure therapie du cancer |
EP2647706B1 (fr) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène |
JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. | 補体阻害剤による慢性障害の治療方法 |
US9051365B2 (en) | 2011-12-21 | 2015-06-09 | Novartis Ag | Antibodies that bind factor P |
DK2817329T3 (en) | 2012-02-20 | 2019-04-01 | Swedish Orphan Biovitrum Ab Publ | Polypeptides Binding to Human Complement Component C5. |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分c5拮抗劑之篩選分析 |
DK2920201T3 (da) | 2012-11-15 | 2020-04-14 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder |
BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
RU2018125515A (ru) * | 2013-01-31 | 2018-10-29 | СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН | Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний |
WO2014152391A1 (fr) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Analogues de compstatine pénétrant dans les cellules et leurs utilisations |
SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
CN116987154A (zh) | 2013-08-28 | 2023-11-03 | 阿菲博迪公司 | 具有突变的支架的结合多肽 |
PT3038633T (pt) | 2013-08-28 | 2021-01-14 | Ipc Res Llc | Polipéptidos estáveis que se ligam ao complemento humano c5 |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
EP3110445A4 (fr) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Anticorps rfb4 humanisés anti-cd22 |
MA39934A (fr) | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
KR102515796B1 (ko) | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
EP3313443B9 (fr) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer |
EP3316885B1 (fr) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Immunoconjugués d'anticorps sn-38 avec un lieur cl2a |
EP3359555B1 (fr) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Régimes posologiques |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
AU2017283470B2 (en) | 2016-06-14 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies and uses thereof |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
KR102514175B1 (ko) | 2017-01-31 | 2023-03-29 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals Inc | regimes de dosagem e composições e métodos relacionados |
JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗c5抗体組み合わせ物およびその使用 |
KR20200033225A (ko) | 2018-08-01 | 2020-03-27 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
WO2021019033A1 (fr) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Schéma posologique et d'administration pour le traitement ou la prévention de maladies liées à c5 par l'utilisation de l'anticorps anti-c5 crovalimab |
MX2022001154A (es) | 2019-07-31 | 2022-02-22 | Hoffmann La Roche | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. |
WO2021067526A1 (fr) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Inhibiteurs du complément pour le traitement d'une réponse médiée par le complément induite par un médicament |
CN111171149B (zh) * | 2020-02-23 | 2021-09-07 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c5分子的人源化单链抗体及其应用 |
US20230349887A1 (en) | 2020-05-15 | 2023-11-02 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
WO2022239720A1 (fr) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | Anticorps d'affinité de liaison vis-à-vis d'antigènes réduite |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5506247A (en) | 1988-04-15 | 1996-04-09 | T Cell Sciences, Inc. | Compounds that inhibit complement and/or suppress immune activity |
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
CA2186108A1 (fr) * | 1994-03-23 | 1995-09-28 | Scott A. Rollins | Procede permettant de reduire les dysfonctionnements des systemes immunitaire et hemostatique pendant la circulation extra-corporelle |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
US5546808A (en) | 1994-09-06 | 1996-08-20 | Harris Instrument Corporation | Apparatus and method for binocular measurement system |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
US5977076A (en) | 1997-04-14 | 1999-11-02 | Anderson; Byron E. | Method and material for inhibiting complement |
EP0983303B1 (fr) | 1997-05-21 | 2006-03-08 | Biovation Limited | Procede de production de proteines non immunogenes |
DE69835524T2 (de) | 1997-08-26 | 2007-04-05 | Amgen Fremont Inc. | Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg |
-
2001
- 2001-10-04 WO PCT/US2001/031103 patent/WO2002030985A2/fr active Application Filing
- 2001-10-04 EP EP01977478A patent/EP1325033B1/fr not_active Expired - Lifetime
- 2001-10-04 AT AT01977478T patent/ATE449791T1/de active
- 2001-10-04 CA CA2424379A patent/CA2424379C/fr not_active Expired - Lifetime
- 2001-10-04 EP EP16152143.0A patent/EP3031827A1/fr not_active Withdrawn
- 2001-10-04 ES ES09167955.5T patent/ES2483991T3/es not_active Expired - Lifetime
- 2001-10-04 DK DK01977478.5T patent/DK1325033T3/da active
- 2001-10-04 EP EP10179315A patent/EP2281840A3/fr not_active Withdrawn
- 2001-10-04 US US09/682,672 patent/US6534058B2/en not_active Expired - Lifetime
- 2001-10-04 DE DE60140618T patent/DE60140618D1/de not_active Expired - Lifetime
- 2001-10-04 EP EP09167955.5A patent/EP2113516B1/fr not_active Expired - Lifetime
- 2001-10-04 EP EP15154800.5A patent/EP2896631A1/fr not_active Withdrawn
- 2001-10-04 PT PT01977478T patent/PT1325033E/pt unknown
- 2001-10-04 ES ES01977478T patent/ES2333775T3/es not_active Expired - Lifetime
- 2001-10-04 AU AU2001296594A patent/AU2001296594A1/en not_active Abandoned
-
2010
- 2010-03-10 HK HK10102519.6A patent/HK1134508A1/xx not_active IP Right Cessation
-
2015
- 2015-12-02 HK HK15111863.4A patent/HK1211043A1/xx unknown
-
2016
- 2016-12-07 HK HK16113934A patent/HK1225741A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DE60140618D1 (de) | 2010-01-07 |
EP1325033B1 (fr) | 2009-11-25 |
EP2281840A3 (fr) | 2012-05-23 |
EP2281840A2 (fr) | 2011-02-09 |
CA2424379C (fr) | 2013-10-01 |
EP2113516A1 (fr) | 2009-11-04 |
PT1325033E (pt) | 2010-04-15 |
ES2333775T3 (es) | 2010-03-01 |
HK1225741A1 (zh) | 2017-09-15 |
ATE449791T1 (de) | 2009-12-15 |
HK1211043A1 (en) | 2016-05-13 |
EP2896631A1 (fr) | 2015-07-22 |
US6534058B2 (en) | 2003-03-18 |
EP2113516B1 (fr) | 2014-05-21 |
WO2002030985A2 (fr) | 2002-04-18 |
EP3031827A1 (fr) | 2016-06-15 |
AU2001296594A1 (en) | 2002-04-22 |
US20020041875A1 (en) | 2002-04-11 |
WO2002030985A3 (fr) | 2002-12-05 |
ES2483991T3 (es) | 2014-08-08 |
EP1325033A2 (fr) | 2003-07-09 |
DK1325033T3 (da) | 2010-04-06 |
CA2424379A1 (fr) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225741A1 (zh) | 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 | |
CY1108663T1 (el) | Αναστολεις της ενεργοποιησης συμπληρωματος | |
WO2001070818A8 (fr) | Inhibiteurs anti-c2/c2a d'activation de complement | |
NO2006008I2 (no) | Natalizumab, anti alfa-4 integrin humanized monoclonal antibody | |
WO1998057994A3 (fr) | Anticorps opsoniques, monoclonaux protecteurs, et chimeres specifiques a l'acide lipoteichoique des bacteries gram positif | |
KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
NZ611387A (en) | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment | |
NZ596723A (en) | Human antibodies that bind human il-12 and methods for producing | |
CA2149120A1 (fr) | Anticorps monoclonal se liant specifiquement a l'endothelium vasculaire tumoral et utilisations de cette substance | |
EP1112085A4 (fr) | Antithrombotique et anticorps monoclonal humanise anti-facteur von willebrand | |
WO2003075846A3 (fr) | Utilisations d'anticorps 8h9 monoclonaux | |
WO2002074251A3 (fr) | Traitement par anticorps monoclonal du cancer du pancreas | |
EP1546205A4 (fr) | Procede destine a reguler le cancer | |
DE69922834D1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
WO2002094194A3 (fr) | Compositions et methodes d'inhibition d'une metastase | |
IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20211003 |